A foamable composition, containing a saccharide for use in the treatment of various disorders including: water, a saccharide, about 0.2% to about 5% by weight of a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric agent selected from a bio-adhesive agent, a gelling ag
A foamable composition, containing a saccharide for use in the treatment of various disorders including: water, a saccharide, about 0.2% to about 5% by weight of a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric agent selected from a bio-adhesive agent, a gelling agent, a film forming agent and a phase change agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
대표청구항▼
The invention claimed is: 1. A foamable saccharide composition for topical administration to the skin or vaginal body cavity including: (i) water; (ii) about 50% to about 80% by weight of a saccharide selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, a suga
The invention claimed is: 1. A foamable saccharide composition for topical administration to the skin or vaginal body cavity including: (i) water; (ii) about 50% to about 80% by weight of a saccharide selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, a sugar alcohol and mixtures thereof; or honey, in an amount that provides about 50% to about 80% by weight of a mixture of saccharides in the composition; (iii) about 0.2% to about 5% by weight of a surface-active agent; (iv) about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and phase change agent; and (v) a foam adjuvant, the foam adjuvant comprising a fatty alcohol or a fatty acid, or a mixture thereof; and a liquefied hydrocarbon propellant or compressed gas propellant at a concentration of about 3% to about 25% of the total composition; wherein the saccharide composition is hygroscopic; and wherein the composition forms a breakable foam upon dispensing. 2. The saccharide composition of claim 1, further containing a hydrophobic solvent. 3. The saccharide composition of claim 2, wherein the composition is in the form of an oil in water emulsion. 4. The saccharide composition of claim 2, wherein the composition is in the form of a water in oil emulsion. 5. The saccharide composition of claim 1, further containing an additive selected from the group of a keratolytic agent and a polar solvent. 6. The saccharide composition of claim 1, further containing at least one active agent selected from the group of an active herbal extract, an acaricide, an age spot and keratose removing agent, an allergen, an analgesic agent, a local anesthetic, an antiacne agent, an antiallergic agent, an antiaging agent, an antibacterial agent, an antibiotic agent, an antiburn agent, an anticancer agent, an antidandruff agent, an antidepressant, an antidermatitis agent, an antiedemic agent, an antihistamine, an antihyperkeratolyte agent, an antiinflammatory agent, an antiirritant, an antilipemic agent, an antimicrobial agent, an antimycotic agent, an antiproliferative agent, an antioxidant, an anti-wrinkle agent, an antipruritic agent, an antipsoriatic agent, an antirosacea agent, an antiseborrheic agent, an antiseptic agent, an antiswelling agent, an antiviral agent, an antiyeast agent, an astringent, a topical cardiovascular agent, a chemotherapeutic agent, a corticosteroid, a dicarboxylic acid, a disinfectant, a fungicide, a hair growth regulator, a hormone, a hydroxy acid, an immunosuppressant, an immunoregulating agent, an insecticide, an insect repellent, a keratolytic agent, a lactam, a metal, a metal oxide, a mitocide, a neuropeptide, a non-steroidal anti-inflammatory agent, an oxidizing agent, a pediculicide, a photodynamic therapy agent, a retinoid, a scabicide, a self tanning agent, a skin whitening agent, a vasoconstrictor, a vasodilator, a vitamin, a vitamin D derivative, a wound healing agent and a wart remover. 7. The saccharide composition of claim 1, wherein the concentration of the saccharide is sufficient to provide a Aw value less than 0.9 or about 0.9. 8. The saccharide composition of claim 1, further containing a therapeutically effective concentration of an anti-infective agent. 9. The saccharide composition of claim 8, wherein the anti-infective agent is selected from the group consisting of an antibiotic agent, an antibacterial agent, an antifungal agent, an agent that controls yeast, an antiviral agent and an antiparasitic agent. 10. The saccharide composition of claim 9, wherein the antibiotic agent is selected from the group consisting of a beta-lactam antibiotic, an aminoglycoside, an ansa-type antibiotic, an anthraquinone, an azole, metronidazole, an antibiotic glycopeptide, a macrolide, erythromycin, clindamycin, an antibiotic nucleoside, an antibiotic peptide, polymyxin B, an antibiotic polyene, an antibiotic polyether, an antibiotic quinolone, an antibiotic steroid, fucidic acid, mupirocin, chloramphenicol, a sulfonamide, tetracycline, an antibiotic metal, silver, copper, zinc, mercury, tin, lead, bismuth, cadmium, chromium, an oxidizing agent, iodine, iodate, a periodate, a hypochlorite, a permanganate, a cationic antimicrobial agent, a quaternary ammonium compound, a biguanide, chlorohexidine, a triguanide, a bisbiguanide, a polymeric biguanide, a naturally occurring antibiotic compound and salts, ions and complexes thereof. 11. The saccharide composition of claim 9, wherein the antifungal agent is useful in the treatment of an infection of dermatophytosis, microsporum, trichophyton and epidermophyton infections, candidiasis, oral candidiasis (thrush), yeast and candida. 12. The saccharide composition of claim 9, wherein the antifungal agent is selected from the group consisting of a polyene, natamycin, nystatin; an allylamine, naftifine, terbinafine; an imidazole, bifonazole, clotrimazole, econazole, fenticonazole, ketocanazole, miconazole, oxiconazole; a diazole, a triazoles, fluconazole, itraconazole, terconazole, tolnaftate, ciclopirox, undecylenic acid, sulbentine, griseofulvin, Amphotericin B, flucytosine (5FC), a morpholine compound, amorolfine, and the related morpholines and salts thereof, and any combination thereof at a therapeutically effective concentration. 13. The saccharide composition of claim 5, wherein the keratolytic agent is selected from the group consisting of urea, an alpha-hydroxy acid, lactic acid, phenol, resorcinol, salicylic acid, a keratolytic enzyme, a proteolytic enzyme and papain. 14. A method of treatment of a disorder of a target site comprising: administering to a target site in need of treatment, said target site selected from the group consisting of the skin, a body surface, a body cavity or mucosal surface, the nasal cavity, the mouth, the eye, the ear canal, the vagina and the rectum; a saccharide composition comprising: (i) water; (ii) about 50% to about 80% by weight of a saccharide selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, a sugar alcohol and mixtures thereof; or honey, in an amount that provides about 50% to about 80% by weight of a mixture of saccharides in the composition; (iii) about 0.2% to about 5% by weight of a surface-active agent; (iv) about 0.01% to about 5% by weight of at least one polymeric agent selected from a bio-adhesive agent, a gelling agent, a film forming agent and a phase change agent; and (v) a foam adjuvant, the foam adjuvant comprising a fatty alcohol or a fatty acid, or a mixture thereof; and a liquefied hydrocarbon propellant or compressed gas propellant at a concentration of about 3% to about 25% of the total composition; wherein the saccharide composition is hygroscopic; and wherein the composition forms a breakable foam upon administration. 15. The method of claim 14, wherein the disorder comprises an infection. 16. The method of claim 15, wherein the infection is selected from the group consisting of a bacterial infection, a fungal infection, a yeast infection, a viral infection and a parasitic infection. 17. The method of claim 14, wherein the disorder is selected from the group consisting of wound, ulcer and burn. 18. The method of claim 14, wherein the disorder is selected from the group consisting of dermatological pain, dermatological inflammation, acne, acne vulgaris, inflammatory acne, non-inflammatory acne, acne fulminans, nodular papulopustular acne, acne conglobata, dermatitis, bacterial skin infections, fungal skin infections, viral skin infections, parasitic skin infections, skin neoplasia, skin neoplasms, pruritis, cellulitis, acute lymphangitis, lymphadenitis, erysipelas, cutaneous abscesses, necrotizing subcutaneous infections, scalded skin syndrome, folliculitis, furuncles, hidradenitis suppurativa, carbuncles, paronychial infections, rashes, erythrasma, impetigo, ecthyma, yeast skin infections, warts, molluscum contagiosum, trauma or injury to the skin, post-operative or post-surgical skin conditions, scabies, pediculosis, creeping eruption, eczemas, psoriasis, pityriasis rosea, lichen planus, pityriasis rubra pilaris, edematous, erythema multiforme, erythema nodosum, granuloma annulare, epidermal necrolysis, sunburn, photosensitivity, pemphigus, bullous pemphigoid, dermatitis herpetiformis, keratosis pilaris, callouses, corns, ichthyosis, skin ulcers, ischemic necrosis, miliaria, hyperhidrosis, moles, Kaposi's sarcoma, melanoma, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, poison ivy, poison oak, contact dermatitis, atopic dermatitis, rosacea, purpura, moniliasis, candidiasis, baldness, alopecia, Behcet's syndrome, cholesteatoma, Dercum disease, ectodermal dysplasia, gustatory sweating, nail patella syndrome, lupus, hives, hair loss, Hailey-Hailey disease, chemical or thermal skin burns, scleroderma, aging skin, wrinkles, sun spots, necrotizing fasciitis, necrotizing myositis, gangrene, scarring, vitiligo, chlamydia infection, gonorrhea infection, herpes, HIV/AIDS, human papillomavirus (HPV), genital warts, bacterial vaginosis, candidiasis, chancroid, granuloma Inguinale, lymphogranuloma venereum, mucopurulent cervicitis (MPC), molluscum contagiosum, nongonococcal urethritis (NGU), trichomoniasis, vulvar disorders, vulvodynia, vulvar pain, yeast infection, vulvar dystrophy, vulvar intraepithelial neoplasia (VIN), contact dermatitis, pelvic inflammation, endometritis, salpingitis, oophoritis, genital cancer, cancer of the cervix, cancer of the vulva, cancer of the vagina, vaginal dryness, dyspareunia, anal and rectal disease, anal abscess/fistula, anal cancer, anal fissure, anal warts, Crohn's disease, hemorrhoids, anal itch, pruritus ani, fecal incontinence, constipation, polyps of the colon and rectum. 19. The saccharide composition of claim 7, wherein the concentration of the saccharide is selected to provide a Aw value less than 0.7 or about 0.7. 20. The saccharide composition of claim 1 wherein the HLB of the surface-active agent is between about 2 and about 9. 21. The saccharide composition of claim 1, wherein the HLB of the surface-active agent is between about 9 and about 14. 22. The saccharide composition of claim 1, wherein the composition has an Aw value of less than 0.9 or about 0.9. 23. A foamable saccharide composition for topical administration comprising: (i) water; (ii) about 50% to about 80% by weight of a saccharide selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, a sugar alcohol and mixtures thereof; or honey in an amount that provides about 50% to about 80% by weight of a mixture of saccharides in the composition; (iii) about 0.2% to about 5% by weight of a surface-active agent; and (iv) a liquefied hydrocarbon propellant or compressed gas propellant at a concentration of about 3% to about 25% of the total composition, wherein the saccharide composition is hygroscopic; and wherein the composition forms a breakable foam upon dispensing. 24. A foamable saccharide composition for topical administration including: (i) water; (ii) about 50% to about 80% by weight of a saccharide selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, a sugar alcohol and mixtures thereof; or honey in an amount that provides about 50% to about 80% by weight of a mixture of saccharides in the composition; (iii) about 0.2% to about 5% by weight of a surface-active agent; and (iv) a liquefied hydrocarbon propellant or compressed gas propellant at a concentration of about 3% to about 25% of the total composition, wherein the foam is capable of providing an Aw value of less than about 9; and wherein the foam forms a breakable foam upon dispensing. 25. A method for delivering a saccharide composition, comprising (a) charging a container with a composition comprising a foamable carrier and a liquefied or compressed gas hydrocarbon propellant, wherein the propellant is present at a concentration of about 3% to about 25% by weight of the total composition, and wherein the carrier comprises (i) water; (ii) about 50% to about 80% by weight of a saccharide selected from the group consisting of a monosaccharide, a disaccharide, an oligosaccharide, a sugar alcohol and mixtures thereof; (iii) optionally honey, in an amount that provides about 50% to about 80% by weight of a mixture of saccharides in the composition; (iv) about 0.2% to about 5% by weight of a surface-active agent; (v) about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and (vi) a foam adjuvant, the foam adjuvant comprising a fatty alcohol or a fatty acid, or a mixture thereof; and (b) dispensing the composition onto a body surface or in a body cavity, wherein the composition is dispensed as a breakable foam. 26. The method of claim 25, wherein the breakable foam creates a semi-occlusive layer on the surface or body cavity. 27. A foamable composition for topical administration to the skin or vaginal body cavity including: (i) water; (ii) about 50% to about 80% by weight of a sugar alcohol; (iii) about 0.2% to about 5% by weight of a surface-active agent; (iv) about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and phase change agent; and (v) a liquefied hydrocarbon propellant or compressed gas propellant at a concentration of about 3% to about 25% of the total composition, and wherein the saccharide composition is hygroscopic; and wherein the composition forms a breakable foam upon dispensing. 28. The foamable composition of claim 27, further comprising a foam adjuvant, the foam adjuvant comprising a fatty alcohol or a fatty acid, or a mixture thereof.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (168)
Spitzer ; Joseph G. ; Small ; Marvin ; Osipow ; Lloyd I. ; Marra ; Dorot hea C., Aerosol container with position-sensitive shut-off valve.
Varco Joseph J. (Fairfield CT) Wis-Surel Gabriela M. (Milford CT) Jachowicz Janusz (Bethel CT), Aerosol hair setting composition containing an alginate.
Ramirez Jose E. (Trumbull CT) Vishnupad Mohan (Monroe CT), Anhydrous foaming composition containing low concentrations of detergents and high levels of glycerin amd emollients suc.
Kanios David P. ; Gentile Joseph A. ; Mantelle Juan A. ; Sablotsky Steven, Compositions and methods for topical administration of pharmaceutically active agents.
Gutierrez Adriana Urrutia ; Albanese Joseph James ; Bianchini Robert Joseph ; Fantano Steven Louis, Cosmetic compositions with DBS and functionalized silicones.
Fowler Timothy J. (Cincinnati OH) Woodin ; Jr. Frederick W. (Middletown OH) Deckner George E. (Cincinnati OH) Gupte Anil J. (Cincinnati OH) Taniguchi Tatsuya (Hyogo JPX) Collias Dimitris I. (Cincinna, Foaming cleansing products.
Chaudhary, Sarita; van Rooijen, Gijs; Moloney, Maurico; Singh, Surindor, Legume-like storage protein promoter isolated from flax and methods of expressing proteins in plant seeds using the promoter.
Broberg Berndt F. J. (Sdertlje SEX) Evers Hans C. A. (Sdertlje SEX), Local anesthetic mixture for topical application and method for obtaining local anesthesia.
Katz David H. ; Pope Laura E. ; Khalil Mohammed H. ; Marcelletti John F. ; Katz Lee R., Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition.
Czarniecki Christine W. (San Francisco CA) Palladino Michael A. (Foster City CA) Shefter Eli (San Francisco CA), Method for the treatment of grafts prior to transplantation using TGF-b
상세보기
Breton Lionel,FRX ; De Lacharriere Olivier,FRX, Method for treatment of acne and/or the effects of ageing using HMG-coenzyme A-reductase inhibitor and compositions for.
Jones Julie Irene,GBX ; Baker Anthony Richard,GBX ; Halls Neil Graham,AUX ; Watmough Peter,GBX ; Marriott Peter,GBX, Method of treating a skin disease with a corticosteroid-containing pharmaceutical composition.
Schmidt Robert R. (Ft. Wright KY) Fortna Raymond H. (Cincinnati OH) Beyer Harold H. (Cincinnati OH), Mild skin cleansing aerosol mousse with skin feel and moisturization benefits.
Glover David A. (Midland MI) LeGrow Gary E. (Midland MI) Madore Linda M. (Midland MI) Malczweski Regina M. (Midland MI), Moisturizing compositions containing organosilicon compounds.
Glover David A. (Midland MI) LeGrow Gary E. (Midland MI) Madore Linda M. (Midland MI) Malczweski Regina M. (Midland MI), Moisturizing compositions containing organosilicon compounds.
Chien Yie W. (North Brunswick NJ) Nair Mona (Highland Park NJ), Mucosal adhesive device for long-acting delivery of pharmaceutical combinations in oral cavity.
Helioff Michael W. (Westfield NJ) Tazi Mohammed (Wayne NJ) Login Robert B. (Oakland NJ) Tancredi John F. (Kinnelon NJ) Kopolow Stephen L. (Plainsboro NJ) Burlant William J. (Wayne NJ), Non-aerosol shaving gel.
Szab Anna Z. (Budapest HUX) Gal Joszef (Budapest HUX) Mrmarosi Katalin (Budapest HUX) Sebestyn Gyula (Budapest HUX) Miholics Gizella (Budapest HUX) Kovcs Mrta (Budapest HUX), Pharmaceutical composition and process for the preparation thereof.
Egidio Marchi (Casalecchio di Reno ITX) Gabriele Rotini L. (Bologna IL ITX) Subhash Desai (Grayslake IL) Massimo Grillli (Highland Park IL), Pharmaceutical compositions containing rifaximin for treatment of vaginal infections.
Griat Jacqueline (Ablon FRX) Ayache Liliane (Paris FRX), Process for the preparation of foams which can be used in the cosmetics and pharmaceutical field and foams obtained by t.
Harm M. Deckers CA; Gijs van Rooijen CA; Joseph Boothe CA; Janis Goll CA; Maurice M. Moloney CA, Products for topical applications comprising oil bodies.
Rodgers Kathleen E. (Long Beach CA) Dizerega Gere S. (Pasadena CA), Retinoid-based compositions and method for preventing adhesion formation using the same.
Grollier Jean F. (Paris FRX) Caudet Alain (Boulogne-Billancourt FRX), Shaving composition for the skin based on polyorgano-siloxanes containing an acyloxyalkyl group and process for use.
Victor Steven A. (301 E. 79th St. New York NY 10021), Shaving cream composition for the treatment of acne vulgaris and pseudofolliculitis barbae and method of producing and u.
Kopolow Stephen L. (Plainsboro NJ) Burlant William J. (Wayne NJ) Helioff Michael W. (Westfield NJ) Bires Carmen D. (Hackettstown NJ) Login Robert B. (Oakland NJ) Tazi Mohammed (Marietta GA), Skin care compositions containing discrete microdroplets of an oil in water stabilized by in situ polymerization of wate.
London Jean (351 Main St. ; Apt. 316 ; P.O. Box 998 El Segundo CA 90245) Gibson James O. (351 Main St. ; Apt. 316 ; P.O. Box 998 El Segundo CA 90245), Therapeutic composition for treatment of cuts, burns and abrasions.
Griffin Martin J. (McHenry IL) Kararli Tugrul T. (Skokie IL) Penzotti ; Jr. Stanley C. (Green Oaks IL) Rydzik Rachelle M. (Northbrook IL) Schmidt Cynthia M. (Gurnee IL), Transdermal pentamidine.
Place Virgil A. ; Wilson Leland F. ; Doherty ; Jr. Paul C. ; Hanamoto Mark S. ; Spivack Alfred P. ; Gesundheit Neil ; Bennett Sean R., Treatment of female sexual dysfunction.
Place Virgil A. ; Wilson Leland F. ; Doherty ; Jr. Paul C. ; Hanamoto Mark S. ; Spivack Alfred P. ; Gesundheit Neil ; Bennett Sean R., Treatment of female sexual dysfunction.
Place Virgil A. ; Wilson Leland F. ; Doherty ; Jr. Paul C. ; Hanamoto Mark S. ; Spivack Alfred P. ; Gesundheit Neil ; Bennett Sean R., Treatment of female sexual dysfunction.
McKinzie Michael D. (Kansas City MO) Lenahan Elizabeth L. (Olathe KS) Hemling Thomas C. (Lake Winnebago MO), Viscous liquid conditioning topical germicides.
Tamarkin, Dov; Gazal, Elana; Keynan, Rita; Eini, Meir; Schuz, David, Methods for accelerated return of skin integrity and for the treatment of impetigo.
Tamarkin, Dov; Ziv, Enbal; Hazot, Yohan; Schuz, David, Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.